Citius Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Dec 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Dec 27, 2024
CTXR$0.53-3.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
| Preferred · Common Stock · Additional Paid-In · Accumulated · Total Citius Pharmaceuticals, Inc. Stockholders’ · Non-Controlling · Total | ||||||||
|---|---|---|---|---|---|---|---|---|
| Stock | Shares | Amount | Capital | Deficit | Equity | Interest | Equity | |
| Balance, September 30, 2022 | $— | 5,848,504 | $5,848 | $232,508,484 | $(129,688,467) | $102,825,865 | $600,380 | $103,426,245 |
| Issuance of common stock for services | — | 4,000 | 4 | 101,996 | — | 102,000 | — | 102,000 |
| Issuance of common stock upon exercise of stock options | — | 1,867 | 2 | 31,265 | — | 31,267 | — | 31,267 |
| Issuance of common stock in registered direct offering, net of costs of $1,201,818 | — | 500,000 | 500 | 13,797,683 | — | 13,798,183 | — | 13,798,183 |
| Stock-based compensation expense | — | — | — | 6,616,705 | — | 6,616,705 | — | 6,616,705 |
| Net loss | — | — | — | — | (32,542,912) | (32,542,912) | — | (32,542,912) |
| Balance, September 30, 2023 | — | 6,354,371 | 6,354 | 253,056,133 | (162,231,379) | 90,831,108 | 600,380 | 91,431,488 |
| Issuance of common stock for services | — | 15,479 | 15 | 284,161 | — | 284,176 | — | 284,176 |
| Issuance of common stock upon exercise of stock options | — | 2,082 | 2 | (2) | — | — | — | — |
| Issuance of common stock offerings, net of costs | — | 875,311 | 876 | 13,802,808 | — | 13,803,684 | — | 13,803,684 |
| Stock-based compensation expense | — | — | — | 11,839,678 | — | 11,839,678 | — | 11,839,678 |
| Merger, net of transaction costs of $2,358,780 | — | — | — | (3,831,357) | — | (3,831,357) | — | (3,831,357) |
| Minority interest from Merger | — | — | — | (3,711,000) | — | (3,711,000) | 3,711,000 | — |
| Net loss | — | — | — | — | (39,425,839) | (39,425,839) | — | (39,425,839) |
| Net loss attributable to noncontrolling interest | — | — | — | — | 287,000 | 287,000 | (287,000) | — |
| Balance, September 30, 2024 | — | 7,247,243 | $7,247 | $271,440,421 | $(201,370,218) | $70,077,450 | $4,024,380 | $74,101,830 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.